Long-term supply contract with Novo Nordisk / Significant expansion of capacities for autoinjectors
Swiss medical technology manufacturer Ypsomed (Burgdorf; www.ypsomed.com) intends to significantly increase its production capacities for autoinjectors in several steps by 2031. The background for this is a long-term supply contract with Danish pharmaceutical company Novo Nordisk, which is also taking over a “significant part of the investment” for the additional production infrastructure, according to a statement from Switzerland. Autoinjectors are used for the administration of medication for self-treatment. 

A small "prick" for the patient, large quantities for the Swiss manufacturer (Photo: Ypsomed)

So far, the devices – which are marketed under the brand name YpsoMate – have been produced at the two Swiss locations, Burgdorf and Solothurn, as well as in Schwerin, Germany. “As a first step, we will expand our plant in Schwerin,” a company spokesperson said in response to a Plasteurope.com enquiry.

The planning has already begun; the lead time for ordering, setting up, validating and qualifying the machinery is about two years. However, according to the spokesperson, the expansion plans also include considerations for the construction of a first plant in North America. 

Related: UK firm to reclaim laboratory waste

As a result of the measures – Ypsomed is currently also ramping up unit numbers at its main plant in Burgdorf – “significant capacities” should become available for Novo Nordisk over the course of 2025. In order to reduce dependencies, there are also plans to give third-party manufacturers the right to produce the autoinjectors under a licensing model. Concrete volumes, however, were not mentioned in response to the enquiry.

According to the company, the supply contract will not have a significant impact on the outlook for the current 2023/24 financial year; it is only expected to be reflected in the balance sheet beginning in the 2025/26 financial year. In 2022, Ypsomed achieved sales of CHF 497.5 mn (EUR 518 mn) and more than doubled its profit to CHF 51.3 mn. 

The company is growing because more and more types of medication are no longer swallowed but injected at home by the patients themselves. PC/ABS, PC, POM, PA, and PBT are among the materials used for the autoinjectors and the insulin pumps (YpsoPump). “We are working intensively on the use of bioplastics from renewable resources as well as on new packaging concepts to reduce the carbon footprint,” said the spokesperson.
09.10.2023 Plasteurope.com [253641-0]
Published on 09.10.2023
Ypsomed: Langfristiger Liefervertrag mit Novo NordiskGerman version of this article...

© 2001-2024 Plasteurope.com  |  Imprint  |  Privacy  |  Cookie settings

Plasteurope.com is a business information platform for the European plastics industry. It is part of KI Kunststoff Information and PIE Plastics Information Europe, one of the leading content providers for the European plastics industry. We offer daily updated business news and reports, in-depth market analysis, polymer prices and other services for the international plastics industry, including a suppliers guide, career opportunities, a trade name directory and videos.

News | Polymer Prices | Material Databases | Plastics Exchange | Suppliers Guide | Jobs | Register | Advertising

PIE – Plastics Information Europe | KI – Kunststoff Information | KunststoffWeb | Plastics Material Exchange | Polyglobe | K-Profi
© 2001-2024 by Plasteurope.com, Bad Homburg
Date of print: 03.03.2024 09:42:37   (Ref: 524148613)
Text and images are subject to copyright and other laws for protection of intellectual property.
Any duplication or distribution in any media as a whole or in parts requires prior written approval by Plasteurope. URL: http://www.plasteurope.com/news/detail.asp